DDInter1230 DDInter1676
Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Mirtazapine {u} (Compound) resembles {v} (Compound) Mianserin
Mirtazapine {u} (Compound) resembles {v} (Compound) Chlorcyclizine
Mirtazapine {u} (Compound) binds {v} (Gene) HTR2C
Mirtazapine {u} (Compound) upregulates {v} (Gene) AGR2
Mirtazapine {u} (Compound) downregulates {v} (Gene) KIF20A
Mirtazapine {u} (Compound) causes {v} (Side Effect) Cardiomegaly
Mirtazapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Mirtazapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Mirtazapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mirtazapine {u} may lead to a major life threatening interaction when taken with {v} Bupropion
Mirtazapine (Compound) resembles Mianserin (Compound)
Mirtazapine (Compound) resembles Chlorcyclizine (Compound)
Mirtazapine (Compound) binds HTR2C (Gene)
Mirtazapine (Compound) upregulates AGR2 (Gene)
Mirtazapine (Compound) downregulates KIF20A (Gene)
Mirtazapine (Compound) causes Cardiomegaly (Side Effect)
Mirtazapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Mirtazapine may lead to a major life threatening interaction when taken with Bupropion